Published Studies Related to Tussicaps Extended-Release (Hydrocodone / Chlorpheniramine)
Well-designed clinical trials possibly related to Tussicaps Extended-Release (Hydrocodone / Chlorpheniramine)
Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative
colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. [2015]
Comparison of an extended-release formulation of granisetron (APF530) versus
palonosetron for the prevention of chemotherapy-induced nausea and vomiting
associated with moderately or highly emetogenic chemotherapy: results of a
prospective, randomized, double-blind, noninferiority phase 3 trial. [2015]
Comparison of subjective effects of extended-release versus immediate-release
oxycodone/acetaminophen tablets in healthy nondependent recreational users of
prescription opioids: a randomized trial. [2014]
Adjunctive use of controlled-release pregabalin in adults with
treatment-resistant partial seizures: a double-blind, randomized,
placebo-controlled trial. [2014]
Evaluation of a single-dose, extended-release epidural morphine formulation for
pain control after lumbar spine surgery. [2014]
Hydromorphone extended release for neuropathic and non-neuropathic/nociceptive
chronic low back pain: a post hoc analysis of data from a randomized,
multicenter, double-blind, placebo-controlled clinical trial. [2014]
Efficacy of guanfacine extended release assessed during the morning, afternoon,
and evening using a modified Conners' Parent Rating Scale-revised: Short Form. [2014]
Effect of extended-release dexmethylphenidate and mixed amphetamine salts on
sleep: a double-blind, randomized, crossover study in youth with
attention-deficit hyperactivity disorder. [2014]
Evaluation of blood pressure and heart rate in patients with hypertension who
received tapentadol extended release for chronic pain: a post hoc, pooled data
analysis. [2014]
Safety and efficacy of once-daily hydromorphone extended-release versus
twice-daily oxycodone hydrochloride controlled-release in chinese patients with
cancer pain: a phase 3, randomized, double-blind, multicenter study. [2014]
Severity of depression and anxiety are predictors of response to antidepressant
treatment in Parkinson's disease. [2014]
Efficacy of levomilnacipran extended-release in improving functional impairment
associated with major depressive disorder: pooled analyses of five double-blind,
placebo-controlled trials. [2014]
Relapse prevention study of paliperidone extended-release tablets in Chinese
patients with schizophrenia. [2014]
Guaifenesin has no effect on sputum volume or sputum properties in adolescents
and adults with acute respiratory tract infections. [2014]
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular
Intervention Trial (ELIMIT). [2013]
SSRI versus bupropion effects on symptom clusters in suicidal depression: post
hoc analysis of a randomized clinical trial. [2013]
Randomized, double-blind trial of guanfacine extended release in children with
attention-deficit/hyperactivity disorder: morning or evening administration. [2013]
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered
with extended-release niacin in hyperlipidemic patients. [2013]
MRI-measured regression of carotid atherosclerosis induced by statins with and
without niacin in a randomised controlled trial: the NIA plaque study. [2013]
Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of
attention, behavior, and performance benefits in children with
attention-deficit/hyperactivity disorder. [2013]
Trastuzumab: a review of its use in HER2-positive advanced gastric cancer. [2013]
Rationale and design of a multicenter randomized clinical trial of extended
release gabapentin in provoked vestibulodynia and biological correlates of
response. [2013]
Efficacy of extended-release tramadol for treatment of prescription opioid
withdrawal: a two-phase randomized controlled trial. [2013]
Annual cost of relapses and relapse-related hospitalizations in adults with
schizophrenia: results from a 12-month, double-blind, comparative study of
lurasidone vs quetiapine extended-release. [2013]
The cost effectiveness of pharmacological treatments for generalized anxiety
disorder. [2013]
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release
carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a
phase 3 randomised, double-blind trial. [2013]
NWP06, an extended-release oral suspension of methylphenidate, improved
attention-deficit/hyperactivity disorder symptoms compared with placebo in a
laboratory classroom study. [2013]
Cocaine use reduction with buprenorphine (CURB): rationale, design, and
methodology. [2013]
Relationship of negative affect and outcome of an opioid therapy trial among low
back pain patients. [2013]
Hepatic safety of injectable extended-release naltrexone in patients with chronic
hepatitis C and HIV infection. [2012]
Lurasidone in schizophrenia: new information about dosage and place in therapy. [2012]
Abatacept for Crohn's disease and ulcerative colitis. [2012]
Extended-release niacin acutely suppresses postprandial triglyceridemia. [2012]
Levetiracetam in the treatment of alcohol dependence: toward the end of the
story? [2012]
Bilastine: in allergic rhinitis and urticaria. [2012]
Quetiapine: a pharmacoeconomic review of its use in bipolar disorder. [2012]
Role and clinical utility of pramipexole extended release in the treatment of
early Parkinson's disease. [2012]
Analysis of three lamotrigine extended-release clinical trials: comparison of
pragmatic ITT and LOCF methodologies. [2012]
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from
double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. [2012]
A randomized, placebo- and active-controlled study of paliperidone
extended-release as maintenance treatment in patients with bipolar I disorder
after an acute manic or mixed episode. [2012]
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam
extended-release in very heavy drinking alcohol-dependent patients. [2012]
Bupivacaine extended-release liposome injection exhibits a favorable cardiac
safety profile. [2012]
Which anticholinergic drug for overactive bladder symptoms in adults. [2012]
The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral,
cosmetic, submuscular augmentation mammaplasty: a randomized, double-blind,
active-control study. [2012]
Effect of tapentadol extended release on productivity: results from an analysis
combining evidence from multiple sources. [2012]
Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. [2011.12]
Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis. [2011.11.23]
Behavioral Versus Drug Treatment for Overactive Bladder in Men: The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. [2011.11.07]
Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. [2011.11]
Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. [2011.11]
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. [2011.10]
Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial. [2011.10]
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. [2011.10]
Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. [2011.10]
Quetiapine extended release: adjunctive treatment in major depressive disorder. [2011.09.01]
Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. [2011.09]
Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders. [2011.09]
A phase 3, randomized, placebo-controlled trial of DepoFoam(R) bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. [2011.09]
Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. [2011.08.23]
Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. [2011.08.23]
Prior epidural lidocaine alters the pharmacokinetics and drug effects of extended-release epidural morphine (DepoDur(R)) after cesarean delivery. [2011.08]
Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. [2011.08]
Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: A randomized controlled trial. [2011.07.20]
A Randomized, Placebo-controlled Trial of Acetaminophen Extended Release for Treatment of Post-marathon Muscle Soreness. [2011.07.13]
Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients. [2011.07.11]
Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes. [2011.07]
Clinical outcomes during opioid titration following initiation with or conversion to Remoxy(R), an extended-release formulation of oxycodone. [2011.07]
Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. [2011.07]
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. [2011.07]
Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. [2011.07]
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. [2011.07]
QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial. [2011.06.01]
Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers. [2011.06]
Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers. [2011.06]
Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. [2011.06]
Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. [2011.06]
Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. [2011.06]
Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. [2011.06]
Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. [2011.05.20]
Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. [2011.05]
Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. [2011.05]
Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. [2011.05]
Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. [2011.05]
Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. [2011.05]
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. [2011.05]
The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension. [2011.05]
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. [2011.05]
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2011.05]
A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. [2011.05]
Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. [2011.05]
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. [2011.04.30]
The abuse potential of Remoxy((R)), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. [2011.04]
Use of aspirin associates with longer primary patency of hemodialysis grafts. [2011.04]
The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia. [2011.04]
An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. [2011.04]
Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media. [2011.04]
A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. [2011.04]
Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. [2011.03.22]
Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. [2011.03]
Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial. [2011.03]
Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. [2011.03]
|
